GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Zim Laboratories Ltd

Zim Laboratories allots 48,726 ESOP shares to subsidiary employee

FUNDRAISE ● No Immediate Change LOW RISK
📅 Filed on BSE: 18 Apr 2026, 04:15 PM IST  ·  BSE ID: 3be8fd3a-0578-46d4-9812-0e397c1c88ac
View Original BSE Filing (PDF)
💡
In Simple Terms
The company issued 48,726 new shares to an employee in a subsidiary company who exercised stock options at Rs. 77.40 per share.
🤖 AI Summary
  • Board approved allotment of 48,726 equity shares under ESOS 2023 on 18 April 2026
  • Exercise price Rs. 77.40/- per share with premium of Rs. 67.40/- per share
  • Paid-up capital increased from Rs. 53,50,03,110/- to Rs. 53,54,90,370/-
  • Total issued shares increased from 5,35,00,311 to 5,35,49,037 shares
  • Allotted to eligible employee of subsidiary; shares rank pari-passu with existing shares
🔢 Key Numbers — exact figures from BSE filing, not rounded
Equity shares allotted
48,726
Face value per share
Rs. 10/-
Exercise price per share
Rs. 77.40/-
Premium per share
Rs. 67.40/-
Paid-up capital before allotment
Rs. 53,50,03,110/-
Paid-up capital after allotment
Rs. 53,54,90,370/-
Total issued shares before allotment
5,35,00,311
Total issued shares after allotment
5,35,49,037
🏢 How This Affects the Company
💰
Financial Impact
Paid-up equity capital increased by Rs. 4,87,260/- (48,726 shares × Rs. 10 face value). Employee received intrinsic value of Rs. 32,66,864/- (48,726 shares × Rs. 67.40 premium), representing a dilution of 0.091% to existing shareholder base.
⚙️
Operational Impact
Employee retention mechanism activated under subsidiary company structure. Dilution confined to single employee exercising vested options under formal ESOS 2023 framework.
👥 What This Means For Shareholders
✅
Action Required
No action required. Allotment is complete and shares rank pari-passu with existing holdings.
👤
Who Is Affected
All existing shareholders experience passive dilution of 0.091% of equity base. Subsidiary employee receives 48,726 shares with no lock-in, effective immediately from 18 April 2026.
🔍
Management Signal
Active use of ESOS 2023 for subsidiary employee retention under formal vesting schedule. Exercise price of Rs. 77.40/- suggests share price has moved above grant price.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q1 FY27 results — check for ESOS expense impact on P&L and diluted EPS
Next ESOS exercise or vesting — monitor cumulative dilution trend in future filings
Annual report FY26 — verify total ESOS pool outstanding and vesting schedule details
LOW RISK Routine ESOP allotment under pre-approved scheme. Single employee, 0.091% dilution, no operational or financial stress.
💡 Investor Takeaway
Zim Laboratories allotted 48,726 shares at Rs. 77.40 per share on 18 April 2026 under ESOS 2023, increasing paid-up capital from Rs. 53,50,03,110/- to Rs. 53,54,90,370/-. Dilution of 0.091% to shareholder base. No lock-in restrictions applied.
⚖️ Strengths & Concerns

✅ Positives

  • Allotment executed under formal SEBI-approved ESOS 2023 scheme with clear regulatory filing
  • No lock-in period imposed; shares rank pari-passu with existing equity shares

⚠️ Concerns

  • Dilution of 0.091% to paid-up share capital despite modest share count increase
  • Filing provides no disclosure of total ESOS 2023 pool size or vesting schedules outstanding
⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.